Organized around development of next generation antibody: immunoglobulin-like scaffold, Nextagen is anchored in a very different business model from most for-profit firms, Established around the objective of advancing biomedical research by providing researchers with access to innovative technology and fostering a community for exchanging improvements, applications and data, the firm's management has created open technology platforms that biologists can customize and enhance for the community's benefit. Nectagen develops a critical mass of tools and reagents, supports users' development of new modifications and applications, and ensures open access to the technology for the academic community. Nectagen also has designed its platforms using components that are made available to non-profits on the condition that any modifications and derivatives made by the recipient are in turn made available to other non-profits and Nectagen
